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Background: Inherited ichthyoses or Mendelian disorders of cornification (MeDOC) are clinically heterogeneous
disorders with high unmet therapeutic needs, which are characterized by skin hyperkeratosis and scaling. Some
MeDOC types are associated with defects of the epidermal lipid metabolism, resulting in perturbed barrier
permeability and subsequent epidermal hyperplasia, hyperkeratosis and inflammation. An example is the CHILD
(congenital hemidysplasia with ichthyosiform nevus and limb defects) syndrome, an X-linked dominant multisystem
MeDOC caused by mutations in the NSDHL (NAD(P)H steroid dehydrogenase-like protein) gene, which is involved
in the distal cholesterol biosynthetic pathway. The skin manifestations of the CHILD syndrome have been attributed
to two major mechanisms: deficiency of cholesterol, probably influencing the proper corneocyte membrane
formation, and toxic accumulation of aberrant steroid precursors.
Methods: Here we addressed the efficacy of an ointment containing cholesterol and simvastatin, an agent
inhibiting endogenous cholesterol synthesis in a compassionate-use treatment of three patients with CHILD
syndrome. To test the specificity of this therapeutic approach, we applied the same topical treatment to two
patients with other types of MeDOC with disturbed skin lipid metabolism.
Results: The therapy with simvastatin and cholesterol was highly effective and well-tolerated by the CHILD syndrome
patients; only lesions in the body folds represented a therapeutic challenge. No improvement was noted in the patients
with other types of MeDOC.
Conclusions: This therapy is inexpensive and accessible to every patient with CHILD syndrome, because both
simvastatin and cholesterol are available worldwide. Our data provide initial evidence of the specificity of the
therapeutic effect of the simvastatin-cholesterol ointment in CHILD syndrome in comparison to other types of MeDOC.
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Inherited ichthyoses or Mendelian disorders of cornifica-
tion (MeDOC) are a large group of clinically heterogenous
disorders characterized by more or less diffuse hyperkera-
tosis and scaling of the skin, and high unmet therapeutic
needs [1]. The genetic basis is diverse with autosomal
dominant, recessive and X-linked types [2,3]. So far, only
topical modes of treatment with ointments containing
keratolytics and emollients, as well as oral retinoids are
available [4]. These approaches are only symptomatic and* Correspondence: cristina.has@uniklinik-freiburg.de
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unless otherwise stated.do not address the specific pathogenesis of each MeDOC
type. The development of more specific therapies depends
on the elucidation of the underlying gene defect and un-
derstanding of the disease pathogenesis [5].
Epidermal differentiation is a tightly regulated process
where multiple players are involved. The cohesion of the
outermost layer of the epidermis, the stratum corneum,
is assured through the embedment of anucleate kerati-
nocytes, called corneocytes in a lipid-enriched extra-
cellular matrix. This organization resembles a wall, with
the bricks being represented by the corneocytes and the
mortar by the epidermal lipids, cholesterol, ceramides
and free fatty acids [6]. Mutations in genes connected to
the lipid metabolism of the skin result in perturbed barriertd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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hyperkeratosis, inflammation and barrier dysfunction. The
CHILD (congenital hemidysplasia with ichthyosiform ne-
vus and limb defects) syndrome is an X-linked dominant
multisystem MeDOC caused by mutations in the NSDHL
(NAD(P)H steroid dehydrogenase-like protein) gene, which
is involved in the distal cholesterol biosynthetic pathway
[7]. The skin phenotype comprises erythrodermic ichthyo-
sis restricted to the one side of the body, with characte-
ristic wax-like scales. Further, this devastating disease is
associated with ipsilateral hypoplasia of the body, affecting
the development of brain, skeletal structures and viscera
[8]. Two major mechanisms have been suggested to be re-
sponsible for the cutaneous manifestations: the cholesterol
deficiency itself, which probably influences the proper for-
mation of the corneocyte membrane, and the toxic accu-
mulation of the steroid precursors [5].
In this study we addressed the efficacy of the topical
application of an ointment containing cholesterol and
simvastatin, an agent inhibiting the endogenous cho-
lesterol synthesis, in a compassionate-use treatment of
three patients with CHILD syndrome. Initially, a similar
formulation consisting of a lotion containing the cho-
lesterol lowering agent lovastatin and 2% cholesterol was
successfully applied in two patients with CHILD syn-
drome [9]. In addition, Seeger et al. recently mentioned
to have initiated this pathogenesis-based combination
topical therapy in other CHILD syndrome patients with
positive responses [10]. Here we tested the effects of
simvastatin and the specificity of this pathogenesis-basedTable 1 Patients treated with the S/C ointment in this study
Patient no.















Autosomal recessive congenital ichthyosis13
Albaniantherapy and applied the same topical treatment to one
patient with autosomal recessive congenital ichthyosis
and one with X-linked recessive ichthyosis.
Methods
The ointment was produced in analogy to a lotion con-
taining the cholesterol lowering agent lovastatin and 2%
cholesterol as described previously [6,9,11,12]. As an im-
provement of the formulation we employed 2% cholesterol
combined with simvastatin instead of lovastatin, since it
has a higher absorption capacity [13] and is less expensive.
To optimize the skin tolerance and compatibility, we tes-
ted several excipients and selected Unguentum Cordes®,
because simvastatin and cholesterol powder could be dir-
ectly mixed with it. Unguentum Cordes® is an amphiphilic,
hypoallergenic vehicle (INCI: macrogol stearate 400,
glycol. monostearate 44-50, sorbitan monostearate and
petroleum jelly) which is free of lanolin, fragrance and
preserving agents, and is therefore applicable for very sen-
sitive skin. This ointment comprising 2% simvastatin and
2% cholesterol in Unguentum Cordes® will be referred to
as S/C ointment.
For morphological analysis of the skin, immunohisto-
chemistry was performed on frozen tissue sections by use
of the primary antibodies against filaggrin FLG01 (Abcam,
Cambridge, UK), Ki67 (clone MIB-1), CD3 (clone F7.2.38),
CD4 (clone 4B12), CD8 (clone C8/144B), CD20 (clone L26)
and CD68 (clone KP1), and the AEC (3-amino-9-ethyl-
carbazole) system (all from DAKO, Hamburg, Germany)
and haematoxylin as a counter stain. Information on theMutation analysis (gene, mutation on
cDNA and protein level)
Treatment
success
NSDHL: c.613G>A, p.G205S (heterozygous)
Yes
NSDHL: c.628C>T, p.Q210X (heterozygous)
Yes
NSDHL: c.262C>T, p.R88X (heterozygous)
Yes
Deletion of STS (hemizygous)
No
NIPAL4: c.527C>A; p.A176D (homozygous) No
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in Table 1. NSDHL mutation analysis results have been des-
cribed before [7].
Results and discussion
Patient 1 was an 18-year-old woman with CHILD syn-
drome and a sharply demarcated ichthyosiform nevusFigure 1 Clinical features of CHILD nevus before (day 0) and after tre
with a sharply demarcated ichthyosiform nevus on the right side of her body
buttock and inguinal fold. After application of the S/C ointment for 9 months
verrucous lesions that persisted after therapy (yellow arrows). The lower pane
the right side of her buttock and smaller lesions on the face. The patient appl
lesions on the buttocks after 3 weeks and of her facial lesions within 3 monthcovering the right side of her body (Figure 1). Single verru-
cous and exudative crusty lesions were present on the ipsi-
lateral buttock and inguinal fold covering about 20% of the
total body surface. Apart from missing right arm and right
lower leg she was healthy. Initially, the S/C ointment was
applied twice daily only on the abdominal skin. Already
after 2 days substantial improvement was noted and afteratment with the S/C ointment. In the upper panels patient 1 is shown
and single verrucous and exudative crusty lesions on the ipsilateral
the skin lesions have almost completely cleared, except for isolated
ls show photographs of patient 2 who had erythematous scaly lesions on
ied the S/C ointment twice daily. Note significant improvement of the
s.
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skin regions, resulting in almost complete remission of the
erythema and scaling (Figure 1, upper panels). The patient
is in follow-up since more than 18 months and currently,
she applies the S/C ointment once every 3 weeks to main-
tain the remission (around 50 gr/month). Her life quality
improved dramatically with a DLQI (Dermatology Life
Quality Index) score of 15 before treatment to a score of 3,
nine weeks after. She can now regularly participate in out-
door and sport activities, e.g. swimming, and is able to
wear leg prosthesis. The right groin and perivulvar region
showed a slower improvement because of pre-existing
oozing lesions. Swabs revealed colonization with Gram-
positive and -negative bacteria. In these regions clinical
improvement was only achieved after application of oral
antibiotics and topical antiseptic powders to reduce the
discharge. Isolated verrucous lesions (Figure 1, yellow
arrows) persisted after therapy and had to be excised.
Histologic examination revealed features of verruciform
xanthoma, which represents a characteristic sign of CHILD
nevus mainly in body folds [14]. Throughout the follow-up
period laboratory examinations including blood count,
liver and kidney values, electrolytes and blood lipids were
regularly performed and displayed no abnormalities.Figure 2 Morphological analysis of lesional skin of patient 1 before (d
haematoxylin & eosin (H&E) staining of a skin sample of patient 1 before tr
orthohyperkeratosis and marked acanthosis. Lymphocytic infiltrates were fo
as evaluated by H&E was comparable to control skin. Similarly, Ki-67 was st
before treatment, features that were reverted after application of the S/C oPatient 2 with CHILD syndrome was a 38-year-old
woman with erythematous scaly lesions on the right side
of her back and smaller lesions involving her face and
ipsilateral skeletal defects (for details see case 2 in [15].
In the past, her CHILD nevus had been dermabraded
and covered with split skin obtained from a contralateral
unaffected donor region [16]. This approach resulted in
a grafted area free of ichthyotic skin manifestations, be-
sides a triangular region of about 6 × 6 cm on the but-
tock (about 2% of the body surface), where the lesions
reappeared after three grafting attempts. The patient ap-
plied the S/C ointment twice daily and noted significant
reduction of scaling and itching already after one week,
and substantially improved appearance after three weeks
(Figure 1, lower panels). She used the S/C ointment to
treat her facial lesions with similar satisfactory results
(Figure 1). She also reported a considerable improve-
ment of her life quality (the DLQI score dropped from 8
to 1 within 9 weeks of treatment), especially since her
skin lesions were not itchy anymore and her daily acti-
vities less exhausting.
The third patient with CHILD syndrome was a 29-year-
old man with wax-like scales following the Blaschko
lines on the right side of his chest and right arm, anday 0), and 3 months after initiation of treatment (day 90). The
eatment showed zones of parakeratosis intermingled with areas of
und in the dermis. Three months after treatment, the skin morphology
rongly enhanced and filaggrin showed a disturbed staining pattern
intment. Scale bars: 100 μm.
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lower leg (for details see [17]). After one week of applica-
tion of the S/C ointment he noted improvement that be-
came more pronounced after four months. Similar to case
1, however, some thick verrucous lesions persisted on the
leg. Unfortunately, the patient was lost for follow-up.
To assess the effect of the S/C ointment on skin mor-
phology, biopsies were taken from patients 1 and 2 before
initiation of the therapy (day 0) and three months after
daily application of the S/C ointment (day 90). BeforeFigure 3 Evaluation of the inflammatory infiltrate in lesional skin of p
(day 90). In the skin biopsy of patient 1 taken at day 0, infiltrates of CD3 p
CD68 positive infiltrates. These were significantly reduced after 3 months otreatment, the affected epidermis of patient 1 was clearly
hyperproliferative as visualized with Ki-67 staining, and
differentiation was perturbed as shown by the broad stai-
ning of filaggrin in the upper epidermal layers (Figure 2).
After treatment, the epidermal thickness normalized and
the staining patterns of the upper markers were compar-
able to control skin. In the biopsy taken at day 0 infiltrates
of CD3 (mature T-cells) positive inflammatory cells were
present, but we also noted CD4 (mainly T-helper cells),
CD8 (mainly cytotoxic T-cells), CD20 (B-cells) or CD68atient 1 before (day 0) and 3 months after initiation of treatment
ositive inflammatory cells were present, as well as CD4, CD8, CD20 or
f treatment.
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regressed after treatment (Figure 3). Similar results were
obtained for the skin samples of patient 2 (not shown).
These data suggest that depletion of abnormal lipid me-
tabolites and replacement with exogenous cholesterol lead
to reversion of the hyperproliferative and inflammatory
processes in the CHILD nevus.
In order to test the specificity of this therapeutic ap-
proach, we applied the S/C ointment in two further
patients with other types of MeDOC caused by pertur-
bed lipid metabolism pathways. A 16-year-old boy with
X-linked recessive ichthyosis due to a hemizygous deletion
of the steroid sulfatase gene (STS) presented with greyish
scales, especially evident on his neck, upper arms and
lower legs (Table 1). He applied the S/C ointment twice
daily on the right side of his neck and the right arm for
two months, without significant improvement of his skin
condition. Finally, a 13-year-old boy with autosomal reces-
sive congenital ichthyosis due to the homozygous NIPAL4
mutation c.527C > A; p.A176D was treated. Ichthyin, the
polypeptide encoded by the NIPAL4 gene, has been shown
to play a physiologic role within the hepoxilin pathway
and is therefore essential for the lipid processing in the
upper epidermis [18]. Application of the S/C ointment
yielded no satisfactory therapeutic outcome. In both
patients treatment was discontinued after two months
because of insufficient therapeutic response. Nevertheless,
patients with other types of MeDOC with abnormal choles-
terol/lipid biosynthesis would probably profit from similar
topical formulations; how systemic manifestations could be
amended remains to be studied in animal models. Patients
with Conradi-Hünermann-Happle (CHH) syndrome would
almost certainly benefit from the S/C ointment, since the
disease pathogenetic mechanism shares the same pathway
as CHILD syndrome. However, in CHH the ichthyotic le-
sions are transient [19,20]. In a mouse model for ichthyosis
follicularis with atrichia and photophobia (IFAP) syndrome
[21] topical simvastatin improved the skin phenotype [22].
Finally in a patient with Sjögren-Larsson syndrome the
application of a lovastatin 2% and cholesterol 2% water
solution ameliorated the skin condition [12].
Conclusions
We employed S/C ointment to treat three patients with
CHILD nevus, the cutaneous hallmark of CHILD syn-
drome. This therapy was highly effective and well-tole-
rated; a long-term remission of the skin manifestations
was obtained. The ointment is inexpensive and accessible
to most patients with CHILD syndrome, because both
simvastatin and cholesterol are largely available. Lesions
involving the body folds represented a therapeutic chal-
lenge because of colonization with various microbial
strains. Moreover, some recalcitrant lesions showing his-
tological features of verruciform xanthoma had to beexcised. Since no improvement was observed in two pa-
tients with other types of MeDOC, our data suggest that
the therapeutic effect is specific for the CHILD syndrome,
and probably closely related disorders with similar defects
of cholesterol biosynthesis.
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